XML 15 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities    
Net loss attributable to Agrify Corporation $ (72,824) $ (9,446)
Adjustments to reconcile net loss attributable to Agrify Corporation to net cash used in operating activities:    
Depreciation and amortization 2,193 313
Impairment on goodwill and intangible assets 69,904
Amortization of premium on investment securities 1,055 63
Amortization of debt discount 2,735
Amortization of issuance costs 370
Interest on investment securities (1,247) (73)
Early termination of lease 26
Provision for doubtful accounts 8,630
Provision for slow-moving inventory 929
Deferred income taxes (262)
Prepaid and refundable taxes (16)
Compensation in connection with the issuance of stock options 1,893 3,066
Non-cash interest (income) expense (1,010) 46
Gain on extinguishment of notes payable, net (2,685)
Loss from disposal of fixed assets 8 25
Change in fair value of contingent consideration (907)
Change in fair value of warrant liabilities (30,966)
Income attributable to non-controlling interests 4 167
Changes in operating assets and liabilities, net of acquisitions:    
Accounts receivable (4,305) (11,122)
Inventory (20,171) (4,477)
Prepaid expenses and other current assets 785 (2,723)
Right-of-use assets, net 60 25
Accounts payable (2,324) 86
Accrued expenses and other current liabilities (4,049) 12,841
Deferred (expense) revenue, net (1,002) 57
Net cash used in operating activities (50,491) (13,837)
Cash flows from investing activities    
Purchases of property and equipment (9,100) (1,102)
Purchase of securities (211,030) (50,280)
Proceeds from the sale of securities 214,449
Issuance of loan receivables (20,443) (483)
Cash paid for business combination, net of cash acquired (3,513)
Net cash used in investing activities (29,637) (51,865)
Cash flows from financing activities    
Proceeds from issuance of debt and warrants in private placement, net 62,405
Proceeds from issuance of Common Stock and warrants in private placement, net of fees 25,797
Proceeds from IPO, net of fees 56,961
Proceeds from Secondary public offering, net of fees 79,839
Proceeds from exercise of options 19 721
Proceeds from exercise of warrants 2 5
Payments on other financing loans (243)
Payments on insurance financing loans (1,071)
Payments of financing leases (187) (94)
Net cash provided by financing activities 86,722 137,432
Net increase in cash and cash equivalents 6,594 71,730
Cash and cash equivalents at the beginning of period 12,014 8,111
Cash and cash equivalents at the end of period 18,608 79,841
Cash, cash equivalents, and restricted cash and restricted marketable securities at end of period    
Cash and cash equivalents 18,608 79,841
Restricted cash and restricted marketable securities 30,000
Total cash, cash equivalents, and restricted cash and restricted marketable securities at the end of period 48,608 79,841
Supplemental disclosures of non-cash investing activities    
Equipment sold for loan receivable to customer 289
Supplemental disclosures of non-cash flow information    
Initial fair value of warrants 40,496
Financing of prepaid insurance $ 1,928